Microbiome Acquisition and Progression of Inflammation and Airway Disease in Infants and Children With Cystic Fibrosis
What is the purpose of this trial?
Cystic Fibrosis (CF) is a fatal, recessive genetic disorder characterized by progressive
inflammation and lung damage. It is unclear whether current treatment strategies, which
focus on detection and eradication of pathogenic microorganisms in the lung, are the best
way to prevent the initiation of early inflammation and lung damage. This study asks how
early acquisition of microbial flora occurs in infants with CF and healthy baby controls,
and whether this process initiates or influences early inflammation and clinical disease
progression in CF.
- 3 Months - 4 Years
- Yale University
- August 2012
- Last Updated:
- June 12, 2014
- Study HIC#:
Clinicaltrials.gov ID: NCT01661491